PMID- 37557185
OWN - NLM
STAT- MEDLINE
DCOM- 20230811
LR  - 20231213
IS  - 1365-2060 (Electronic)
IS  - 0785-3890 (Print)
IS  - 0785-3890 (Linking)
VI  - 55
IP  - 2
DP  - 2023
TI  - First-generation EGFR-TKI plus bevacizumab and chemotherapy for advanced 
      EGFR-mutated non-squamous non-small-cell lung cancer: a retrospective study.
PG  - 2243967
LID - 10.1080/07853890.2023.2243967 [doi]
LID - 2243967
AB  - BACKGROUND: This study aimed to compare the efficacy and safety of different 
      treatment modalities for previously untreated advanced EGFR-mutated non-squamous 
      non-small-cell lung cancer (NSCLC). METHODS: This retrospective study included 
      196 advanced EGFR-mutated non-squamous NSCLC. 107 received EGFR-tyrosine kinase 
      inhibitor (EGFR-TKI) monotherapy (T), 53 received EGFR-TKI + bevacizumab (T + A), 
      and 36 received EGFR-TKI + bevacizumab + chemotherapy (T + A + C). The endpoints 
      included progression-free survival (PFS), overall survival (OS), objective 
      response rate (ORR) and adverse events (AEs). RESULTS: The median PFS was 
      27 months in the T + A + C group, 17 months in the T + A group, and 10 months in 
      the T group. The multivariate analysis showed lower disease progression in the 
      T + A + C group (HR, 0.377; 95% CI, 0.224-0.634; p < .001). Subgroup analysis 
      showed that the T + A + C group did significantly improve PFS in patients with 
      metastatic organs >/=2, brain metastases, liver metastases, and EGFR 19del compared 
      to T + A group. No significant improvement in OS in the T + A + C group versus 
      the T + A group, but a significant benefit in the subgroup of patients with 
      metastatic organs >/=2. We also performed a subgroup analysis of the T + A + C 
      group versus the T group, which similarly showed that the T + A + C group had 
      better PFS than the T group in most subgroups, and the T + A + C group 
      significantly improved OS in patients with metastatic organ >/=2 and liver 
      metastases compared with the T group. The ORR was significantly higher in the 
      T + A + C group than A + T and T groups (83.3% vs 71.7% vs 60.7%, p = .033). In 
      safety, the T + A + C group had a higher incidence of AEs, but the majority was 
      grade 1-2. The most frequent AEs of grade >/= 3 were leukopenia (8.3%) and 
      increased aminotransferase (8.3%) in the T + A + C group. CONCLUSIONS: 
      First-generation EGFR-TKI plus bevacizumab plus chemotherapy was a promising 
      strategy for advanced EGFR-mutated non-squamous NSCLC.
FAU - Wu, Yahua
AU  - Wu Y
AD  - Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, 
      Fujian, China.
FAU - Du, Bin
AU  - Du B
AD  - Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, 
      Fujian, China.
FAU - Lv, Chengliu
AU  - Lv C
AD  - Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, 
      Fujian, China.
FAU - Ji, Xiaohui
AU  - Ji X
AD  - Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, 
      China.
FAU - Lan, Yanqin
AU  - Lan Y
AD  - Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, 
      Fujian, China.
FAU - Yao, Na
AU  - Yao N
AD  - Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, 
      Fujian, China.
FAU - Zhu, Yingjiao
AU  - Zhu Y
AD  - Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, 
      Fujian, China.
FAU - Lai, Jinhuo
AU  - Lai J
AD  - Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, 
      Fujian, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Ann Med
JT  - Annals of medicine
JID - 8906388
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - 0 (Tyrosine Kinase Inhibitors)
SB  - IM
MH  - Humans
MH  - *Bevacizumab/therapeutic use
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics
MH  - ErbB Receptors/genetics
MH  - Liver Neoplasms/secondary
MH  - *Lung Neoplasms/drug therapy/genetics
MH  - Mutation
MH  - Retrospective Studies
MH  - *Tyrosine Kinase Inhibitors/therapeutic use
MH  - Brain Neoplasms/secondary
PMC - PMC10413910
OTO - NOTNLM
OT  - Advanced non-squamous NSCLC
OT  - EGFR mutation
OT  - efficacy
OT  - multi-combination therapy
OT  - safety
COIS- No potential competing interest was reported by the author(s).
EDAT- 2023/08/10 00:42
MHDA- 2023/08/11 06:43
PMCR- 2023/08/09
CRDT- 2023/08/09 18:42
PHST- 2023/08/11 06:43 [medline]
PHST- 2023/08/10 00:42 [pubmed]
PHST- 2023/08/09 18:42 [entrez]
PHST- 2023/08/09 00:00 [pmc-release]
AID - 2243967 [pii]
AID - 10.1080/07853890.2023.2243967 [doi]
PST - ppublish
SO  - Ann Med. 2023;55(2):2243967. doi: 10.1080/07853890.2023.2243967.